Tempus, Penn’s Abramson Cancer Center Collaborate
News Dec 02, 2016
Tempus and Penn’s Abramson Cancer Center have partnered to better determine which patients will have a positive response to immunotherapy treatment based on next generation genomic and transcriptomic sequencing. As part of a research collaboration, Tempus will provide sequencing and analysis of de-identified pancreatic and melanoma cancer patient data to Penn.
Utilizing next-generation sequencing, machine learning and bioinformatics, Tempus will help physicians analyze these data sets for relevant patterns that can help inform which immunotherapies are most likely to be effective in a given cohort of patients. “Tempus is committed to bringing relevant information and technology to healthcare providers battling cancer,” said Eric Lefkofsky, Co-founder and CEO of Tempus.
“We are proud to partner with the Abramson Cancer Center and provide our expertise to the researchers and physicians who are doing innovative and groundbreaking work on the front lines of immunotherapy.” “We are thrilled to collaborate with Tempus, a company that shares our commitment to research and innovation toward the advancement of patient care,” said Dr. Chi Van Dang, Professor & Director, Abramson Cancer Center.
“Putting cutting-edge technology into the hands of our physicians enhances the resources they need to best serve their patients.” “At The University of Pennsylvania’s Abramson Cancer Center, we believe that the cure for cancer is not only within reach, it’s also within each of us,” said Dr. Robert H. Vonderheide, Hanna Wise Professor in Cancer Research at the Perelman School of Medicine at the University of Pennsylvania and Associate Director for Translational Research at the Abramson Cancer Center.
“We are excited to partner with Tempus, who will bring their sequencing and analytic capabilities to our renowned team of researchers working tirelessly to advance our understanding of tumor immunology.”
Source: Story from Tempus. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.